In a rapid communication published in the journal Genes & Diseases, has shed light on the role of the Wnt signaling pathway in influencing the immune response of colorectal cancer (CRC) patients.

Human cancers exhibit genomic instability and an increased mutation rate due to underlying defects in DNA repair. Cancer cells are often defective in one of six major DNA repair pathways, namely: ...

The FDA approved the Dako Omnis panel to identify patients with colorectal cancer with mismatch repair deficiency. The mismatch repair immunohistochemical panel pharmDx (Dako Omnis) has received U.S.

A study reveals a possible explanation for why checkpoint blockade inhibitors don't work well for some patients whose tumors have a high mutational burden. This block ...

S. W. Awwad, N. Ayoub, Overexpression of KDM4 lysine demethylases disrupts the integrity of the DNA mismatch repair pathway. Biol. Open 4, 498–504 (2015). J. E. Loughery et al., DNMT1 deficiency ...

The Dako Omnis test identifies mismatch repair deficiencies in colorectal cancer, aiding in treatment decisions and potentially improving patient outcomes. Hernexeos, a kinase inhibitor, offers a new ...

Researchers from Japan report that they have characterized gene mutations in colorectal cancer (CRC) tumors with high tumor mutation burden that lack mutations in the major oncogenes. Their findings ...